General Archives - Page 11 of 12 - Gilde Healthcare

Menu
Menu
Home

Neuigkeiten
& Einblicke

Gilde Healthcare invests alongside Capital A in Tromp Medical to accelerate international growth in the medical imaging market

Tromp Medical, Europe’s largest independent medical imaging sales and service organization, has attracted Gilde Healthcare as new investor to drive further growth in the medical imaging market. Headquartered in the Netherlands, Tromp Medical specializes in installing and maintaining various medical imaging equipment modalities such as mammography, CT, MRI and ultrasound systems from leading, highly innovative manufacturers, including Canon Medical Systems,...
16. Dezember 2024

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

test SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study in Stargardt disease First ever IND clearance for […]

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

test Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (approx. USD 147 million). With its investment in Noema Pharma, EQT Life […]

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through...

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology’s annual meeting, ACR Convergence 2024, being held from 14 November to 19 November,...

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study evaluating the safety and efficacy of gemlapodect (NOE-105) in...

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant Cell Tumour TANGENT Study Underway with First Patients Dosed SynOx Therapeutics Limited...

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova Partners, Forbion, and British Patient Capital with founding investor Syncona Purespring Therapeutics,...

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in...
Loading...
These were all messages
289e5ae64c